Answers are grounded in this paper and cite their sources.
Achieving a functional cure for chronic hepatitis B remains challenging, primarily due to the inability to reconstitute effective host immune responses against the virus. The unexpected functional cure of chronic hepatitis B following allogeneic hematopoietic stem cell transplantation provides a unique proof-of-principle model for immune-mediated HBsAg clearance. This review aims to elucidate that the core mechanism underlying hematopoietic stem cell transplantation-mediated HBsAg clearance lies in “adoptive immune transfer”, and to explore design principles and future directions for modern cell-based immunotherapies based on this mechanism. We reviewed available case reports and meta-analytic evidence, acknowledging their limitations, and dissected the immunological mechanisms by which donor-derived hepatitis B virus-specific T and B cells may jointly reconstitute adaptive immunity and break host immune tolerance. We then comparatively evaluated the technical characteristics and limitations of chimeric antigen receptor T cell therapy and T-cell receptor-engineered T-cell therapy. Current engineered T-cell therapies, while translating the core principle of adoptive transfer, exhibit fundamental limitations including monoclonal specificity, inability to remodel the host microenvironment, and absence of durable humoral reconstitution. A broader functional-cure strategy may require adopting the paradigm of synergy and systemic immune reshaping exemplified by hematopoietic stem cell transplantation. Future strategies should develop temporally optimized, multilayered combination therapies, offering a possible pathway for next-generation therapeutics capable of systemically rebuilding antiviral immunity.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: